Navigation Links
Celladon Corporation Receives Notice of Allowance from European Patent Office
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has received a Notice of Allowance from the European Patent Office (EPO) for claims that cover MYDICAR, Celladon's first in class drug under clinical evaluation for advanced heart failure. The patent to be issued from this allowed patent application, titled "Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy" carries a patent term to at least 2027. A similar application has been filed with the U.S. Patent and Trademark Office (USPTO).

"This is an important addition to our existing patent portfolio. The allowance strengthens our ability to broadly protect our proprietary technology as we continue the clinical development of MYDICAR," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. "We will continue to complement our existing patent portfolio to further fortify MYDICAR's market exclusivity position."

About MYDICAR®

MYDICAR® is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling and contractility. SERCA2a levels decline in all forms of late-stage heart failure resulting in deficient heart function. With MYDICAR®, the SERCA2a gene is delivered using a recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR® is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. MYDICAR®  is synergistic and additive across current heart failure treatments such as ACE inhibitors, beta-blockers, sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician.

About Heart Failure

Chronic heart failure is a leading cause of hospitalization and is expected to result in direct and indirect costs of $39.2 billion to the U.S. healthcare system in 2010. Nearly 6 million people in the U.S. have heart failure, and at least 670,000 new cases will be diagnosed this year. Heart failure leads to about 280,000 deaths annually. The most common symptoms of heart failure are shortness of breath, feeling tired and swelling in the ankles, feet, legs and sometimes the abdomen. There is no cure.

 

 


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
3. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
4. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
5. Luminex Corporation Reports First Quarter 2012 Results
6. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
7. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
8. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
11. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... , May 25, 2016 Digital ... issuance to it by the US Patent and ... company,s technology includes proprietary processes for electronic opt-­in ... health and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute has partnered ... cessation class starting June 6 at their clinic in downtown Tampa. The class is ... the Lung Institute has created a free downloadable 4 Week Smoking Cessation Guide ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age ... speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the ... a member of the Institute for Functional Medicine. , He also heads up FITTLab, ...
(Date:5/26/2016)... ... 2016 , ... Power Systems, a leading developer and supplier ... Course in Stoughton, Massachusetts. The course was led by Power Systems’ Education Coordinator, ... interactive course to qualify participants as certified PowerWave trainers. , PowerWave is ...
Breaking Medicine News(10 mins):